A gerincmetasztázisok emelkedő incidenciájával párhuzamosan, az elmúlt évek orvostudományi fejlődésének eredményeként a betegek életkilátása és életminősége ugrásszerűen javult. A gerincmetasztázisok kezelése aprólékos, gondos kiértékelést követel, ugyanis az optimális terápia kiválasztása több tényezőn alapul: a tumor típusán, a szegmentális stabilitáson, a páciens tünetein és általános egészségi állapotán. A modern sugárkezelés kombinálása a minimálinvazív sebészeti technológiákkal (minimálinvazív stabilizáció, szeparációs műtét) tartós lokális kontroll lehetőségét nyújtja alacsony komplikációs ráta mellett a betegek relatíve nagy csoportjában. Összefoglaló közleményünkben a gerincmetasztázisok modern, komplex kezelésének elemeit és összehangolt rendszerét mutatjuk be a szakirodalomban publikált evidenciákra támaszkodva. Orv Hetil. 2018; 159(8): 297–302.
Jacobs WB, Perrin RG. Evaluation and treatment of spinal metastases: an overview. Neurosurg Focus 2001; 11: e10.
Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27: 2758–2765.
Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010; 35: E1221–E1229.
Fourney DR, Frangou EM, Ryken TC, et al. Spinal Instability Neoplastic Score: an analysis of reliability and validity from the Spine Oncology Study Group. J Clin Oncol. 2011; 29: 3072–3077.
Fisher CG, Schouten R, Versteeg AL, et al. Reliability of the Spinal Instability Neoplastic Score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases. Radiat Oncol. 2014; 9: 69.
Fisher CG, Versteeg AL, Schouten R, et al. Reliability of the spinal instability neoplastic scale among radiologists: an assessment of instability secondary to spinal metastases. AJR Am J Roentgenol. 2014; 203: 869–874.
Arana E, Kovacs FM, Royuela A, et al. Spine Instability Neoplastic Score: agreement across different medical and surgical specialties. Spine J. 2016; 16: 591–599.
Campos M, Urrutia J, Zamora T, et al. The Spine Instability Neoplastic Score: an independent reliability and reproducibility analysis. Spine J. 2014; 14: 1466–1469.
Teixeira WG, Coutinho PR, Marchese LD, et al. Interobserver agreement for the spine instability neoplastic score varies according to the experience of the evaluator. Clinics (Sao Paulo) 2013; 68: 213–218.
Expert Panel on Radiation Oncology – Bone Metastases: Lo SS, Ryu S, Chang EL, et al. ACR Appropriateness Criteria® metastatic epidural spinal cord compression and recurrent spinal metastasis. J Palliat Med. 2015; 18: 573–584.
Quinn RH, Randall RL, Benevenia J, et al. Contemporary management of metastatic bone disease: tips and tools of the trade for general practitioners. J Bone Joint Surg Am. 2013; 95: 1887–1895.
Ivanishvili Z, Fourney DR. Incorporating the Spine Instability Neoplastic Score into a treatment strategy for spinal metastasis: LMNOP. Global Spine J. 2014; 4: 129–136.
Laufer I, Rubin DG, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 2013; 18: 744–751.
Huisman M, van der Velden JM, van Vulpen M, et al. Spinal instability as defined by the spinal instability neoplastic score is associated with radiotherapy failure in metastatic spinal disease. Spine J. 2014; 14: 2835–2840.
Lam TC, Uno H, Krishnan M, et al. Adverse outcomes after palliative radiation therapy for uncomplicated spine metastases: role of spinal instability and single-fraction radiation therapy. Int J Radiat Oncol Biol Phys. 2015; 93: 373–381.
Lee SH, Tatsui CE, Ghia AJ, et al. Can the spinal instability neoplastic score prior to spinal radiosurgery predict compression fractures following stereotactic spinal radiosurgery for metastatic spinal tumor? A post hoc analysis of prospective phase II single-institution trials. J Neurooncol. 2016; 126: 509–517.
Sahgal A, Atenafu EG, Chao S, et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol. 2013; 31: 3426–3431.
Thibault I, Al-Omair A, Masucci GL, et al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. J Neurosurg Spine 2014; 21: 711–718.
Bollen L, Wibmer C, Van der Linden YM, et al. Predictive value of six prognostic scoring systems for spinal bone metastases: an analysis based on 1379 patients. Spine (Phila Pa 1976). 2016; 41: E155–E162.
Bollen L, van der Linden YM, Pondaag W, et al. Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients. Neuro Oncol. 2014; 16: 991–998.
Choi D, Fox Z, Albert T, et al. Prediction of quality of life and survival after surgery for symptomatic spinal metastases: a multicenter cohort study to determine suitability for surgical treatment. Neurosurgery 2015; 77: 698–708.
Verlaan JJ, Choi D, Versteeg A, et al. Characteristics of patients who survived <3 months or >2 years after surgery for spinal metastases: can we avoid inappropriate patient selection? J Clin Oncol. 2016; 34: 3054–3061.
Laufer I, Zuckerman SL, Bird JE, et al. Predicting neurologic recovery after surgery in patients with deficits secondary to MESCC: systematic review. Spine (Phila Pa 1976). 2016; 41(Suppl 20): S224–S230.
Chang JH, Shin JH, Yamada YJ, et al. Stereotactic body radiotherapy for spinal metastases: what are the risks and how do we minimize them? Spine (Phila Pa 1976). 2016; 41(Suppl 20): S238–S245.
Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976). 2009; 34: S78–S92.
Zuckerman SL, Laufer I, Sahgal A, et al. When less is more: the indications for MIS techniques and separation surgery in metastatic spine disease. Spine (Phila Pa 1976). 2016; 41(Suppl 20): S246–S253.
Helissey C, Champiat S, Soria JC. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015; 27: 108–117.
Wu K, House L, Liu W, et al. Personalized targeted therapy for lung cancer. Int J Mol Sci. 2012; 13: 11471–11496.
Monteiro Ide P, Madureira P, de Vasconscelos A, et al. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. Pharmacogenomics 2015; 16: 257–271.
Menzies AM, Long GV. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol. 2013; 5: 278–285.
Green J, Ariyan C. Update on immunotherapy in melanoma. Surg Oncol Clin N Am. 2015; 24: 337–346.
Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol. 2012; 23(Suppl 8): viii35–viii40.